GENB
Generate Biomedicines, Inc.
Generate Biomedicines (GENB) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- Revenue $6.31M, down 38% from $10.1M a year ago.
- GAAP EPS −$0.52 missed the −$0.49 consensus by $0.03, up from −$1.94 a year ago.
- Generate Biomedicines reported revenue of $6.3 million for the second quarter of 2026.
- The company recorded a net loss of $67.3 million, or $0.52 per share, for the quarter.
- Research and development expenses rose to $64.3 million, driven by ongoing Phase 3 clinical trials.
Results vs analyst consensus
Revenue
Reported
$6.31M
Consensus not captured before release
−38% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.52
Consensus −$0.49
Missed by $0.03GAAP EPS: −$0.52
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company expects to require additional capital to support long-term operations.
- Revenue declined compared to the same period in 2025 due to changes in research program developments.
Read original report
Source: Generate Biomedicines, Inc. press release · SEC Form 8-K exhibit 99.1